Qube Research & Technologies (QRT)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.15M	Sell	479,970 -450,661	-48%	-$7.2M	0.01%	1392
2026 Q1	$13.8M	Buy	930,631 +56,286	+6%	+$823K	0.02%	1090
2025 Q4	$13.9M	Sell	874,345 -278,500	-24%	-$3.95M	0.01%	1124
2025 Q3	$12.7M	Sell	1,152,845 -89,667	-7%	-$979K	0.01%	1168
2025 Q2	$10.5M	Buy	1,242,512 +386,364	+45%	+$3.1M	0.01%	1263
2025 Q1	$6.88M	Buy	856,148 +660,389	+337%	+$5.35M	0.01%	1363
2024 Q4	$1.76M	Buy	+195,759	New	+$1.6M	﹤0.01%	1936
2024 Q2	–	Sell	-172,153	Closed	-$862K	–	3799
2024 Q1	$862K	Buy	+172,153	New	+$1.17M	﹤0.01%	2233
2023 Q4	–	Sell	-71,378	Closed	-$555K	–	4327
2023 Q3	$555K	Buy	+71,378	New	+$698K	﹤0.01%	1983
2023 Q1	–	Sell	-17,545	Closed	-$75.8K	–	2529
2022 Q4	$75.8K	Buy	+17,545	New	+$102K	﹤0.01%	2064
2022 Q2	–	Sell	-111,809	Closed	-$1.38M	–	2481
2022 Q1	$1.38M	Buy	+111,809	New	+$1.73M	0.01%	1000

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AUPH Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Aurinia Pharmaceuticals (AUPH) stake by 48% in Q2 2026, selling an estimated $7.2M and leaving 479,970 shares worth $8.15M. The position accounts for 0.01% of the portfolio, ranked #1392.

Qube Research & Technologies (QRT) first reported a position in AUPH in Q1 2022 and has held it in 11 quarters since. The position peaked at $13.9M in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Qube Research & Technologies (QRT) held 479,970 shares of Aurinia Pharmaceuticals worth $8.15M as of Q2 2026.
Qube Research & Technologies (QRT) sold 450,661 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $7.2M.
Aurinia Pharmaceuticals made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1392 holding.
Qube Research & Technologies (QRT) first reported a position in Aurinia Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
Qube Research & Technologies (QRT)'s Aurinia Pharmaceuticals position peaked at $13.9M in Q4 2025.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.